Sat, Oct 25, 2014, 6:13 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Progenics Pharmaceuticals, Inc. Message Board

  • dramboni dramboni Dec 22, 2011 10:57 AM Flag

    How many bagholders will be left once this hits $5??

    What comes up must come down.
    Just look at AFFY or TEAR.
    Market will take a dump today and tomorrow.

    SortNewest  |  Oldest  |  Most Replied Expand all replies

    • None, but shorts will be covering at much higher prices

    • Moron, Barking harder

    • dramboni,

      I laugh at your ignorance and desperation. This is the sum total of your knowledge about PGNX and why you are so negative.

      <<What comes up must come down.
      Just look at AFFY or TEAR.
      Market will take a dump today and tomorrow. >>

      Yes, that does make me laugh. Thanks so much Mr. desperate short. If you want some real insights input PGNX, then read the following.

      The Motley fool is a pretty mixed bag. The most recent post about PGNX is the kind of worthless and uninformed nonsense I expect from the idiot shorts with an agenda, the kind who are now flooding the board, and it gives the Motley fool a bad name. The resident Motley Fool biotech "expert" actually wrote that that the oral formulation won't increase revenues from Relistor sales much. What a clueless moron!

      1) The advanced medial illness market for sub-cutaneous Relistor is finally growing under Salix as they have commitment to the drug, as opposed to Wyeth. This growth will continue.

      2) PGNX has a PDUFA data of April 2012 for expansion of sub-cutaneuos Relistor into the chronic pain market. This market has been estimated at 10-20x larger than the current chronic pain market. That bodes very well of future sales growth for Relistor.

      3) The phase III data from yesterday was for an oral formulation of Relistor, and it will be submitted to the FDA by the middle of next year. This bodes extremely well for both the advanced medical and chronic pain markets.

      4) PGNX currently has a monopoly in the opiate induced constipation market, and the oral formulation will ensure PGNX/Salix remains the dominant player, even if NKTR can get approved in the chronic pain market in 2 or 3 years.

      5) The idiot from the Motley Fool didn't even get the basics for the PSMA project correct. It is the conjugated anti-PMSA antibodies, not the vaccine, which is the lead drug in PGNX's prostate cancer project.

      • 1 Reply to dr.vinmantoo
      • Where is the approval from the FDA??
        This stock has been so overhyped and overbought is it not even funny.
        Have you noticed how this is slowly pulling back?
        Lets wait another week.
        I bet ya that this will be at $7 before you see $10.
        I am not desperate but it seems the company is.
        Just look at their income sheet.
        People are unreal buying based at stupid news.
        Next eaning report will disapoint and this babe will go back to $4.
        Once it gets approval it will spike and pull right back.
        And a merry x-mas to you.

    • 0, because it won't. But thanks for your valuable input :-D

    • Guys, are you gonna make this drop so I can add more or what?!


4.72+0.11(+2.39%)Oct 24 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.